Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark studyHesham Eissa, Luigi D. Notarangelo, Monica S. Thakar et al.|Journal of Allergy and Clinical Immunology|2023Cited by 21
Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcelAkshay Sharma, Haydar Frangoul, Franco Locatelli et al.|Blood Advances|2025Cited by 4
Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell DiseaseHaydar Frangoul, Stephan A. Grupp, Franco Locatelli et al.|Blood|2024Cited by 3
Skeletal Biology and Late Effects Following Allogeneic Transplantation for Pediatric Hematologic Malignancy: A Ptctc and CIBMTR Multicenter StudyChristine Duncan, K. Scott Baker, James A. Connelly et al.|Transplantation and Cellular Therapy|2023Cited by 1
Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121Stephan A. Grupp, Haydar Frangoul, Franco Locatelli et al.|Blood|2025Cited by 1